Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium
- 1 March 2006
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 100 (3) , 501-505
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Phase III Trial of Doxorubicin With or Without Cisplatin in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2004
- Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2004
- Paclitaxel and Carboplatin, Alone or With Irradiation, in Advanced or Recurrent Endometrial Cancer: A Phase II StudyJournal of Clinical Oncology, 2001
- Chemotherapy in gynecologic cancerCurrent Opinion in Oncology, 1998
- Chemotherapy as Adjuvant and Salvage Treatment in Women With Endometrial CarcinomaClinical Obstetrics and Gynecology, 1996
- Phase II Trial of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced/Recurrent Endometrial CarcinomaGynecologic Oncology, 1995
- Phase II trial of clsplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A gynecologic oncology group studyGynecologic Oncology, 1989
- Phase II Evaluation of Carboplatin in Advanced Endometrial Carcinoma1JNCI: Journal of the National Cancer Institute, 1988